• Entrada Therapeutics to Present at William Blair Biotech Focus Conference

    Source: Nasdaq GlobeNewswire / 06 Jul 2022 06:00:00   America/Chicago

    BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the Company will participate in-person at the William Blair Biotech Focus Conference, to be held in New York from July 12 – 13, 2022.

    A fireside chat with Dipal Doshi, President and Chief Executive Officer, and Natarajan Sethuraman, PhD, Chief Scientific Officer, will be available to view beginning Monday, July 11, 2022 at 9:00 a.m. Eastern Time on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event.

    About Entrada Therapeutics
    Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).

    For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

    Investor and Media Contact
    Karla MacDonald
    VP, Corporate Communications and Investor Relations
    kmacdonald@entradatx.com


    Primary Logo

Share on,